Investors in Gilead Sciences (NASDAQ: GILD) have seen their investments grow 35% per year for the past five years, and 58% over the last 12 months. Since our conversation about Gilead with Eugene Groysman in June, the stock has appreciated 29%. After a stock has done this well, it is only natural to ask whether it can keep going, or whether it's time to sell. To answer that question, I talked to 2 Marketocracy Masters, Eugene Groysman and Mike Koza, to discuss whether Gilead can double again.
Investors in Gilead Sciences (NASDAQ: GILD) have seen their investments grow 35% per year for the past five years, and 58% over the last 12 months. Since our conversation about Gilead with Eugene Groysman in June, the stock has appreciated 29%. After a stock has done this well, it is only natural to ask whether it can keep going, or whether it's time to sell. To answer that question, I talked to 2 Marketocracy Masters, Eugene Groysman and Mike Koza, to discuss whether Gilead can double again.
Share this Article
Comment on this Article
Recommended
Please to comment